Nanobiotix S.A. (LON:0QAV)
London
· Delayed Price · Currency is GBP · Price in EUR 2.860
-0.035 (-1.21%)
At close: Apr 28, 2025
Nanobiotix Revenue
In the year 2024, Nanobiotix had annual revenue of -7.19M EUR, down -119.86%. Nanobiotix had revenue of -16.48M in the half year ending December 31, 2024, a decrease of -578.07%.
Revenue
-7.19M EUR
Revenue Growth
-119.86%
P/S Ratio
-19.28
Revenue / Employee
-66.57K EUR
Employees
108
Market Cap
114.61M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
| Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |
Nanobiotix News
- 25 days ago - Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Nanobiotix GAAP EPS of -€1.44 - Seeking Alpha
- 26 days ago - NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire
- 4 weeks ago - Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC - GlobeNewsWire
- 5 weeks ago - NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference - GlobeNewsWire
- 6 weeks ago - Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden - Benzinga
- 6 weeks ago - NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 - GlobeNewsWire